ASTRAZENECA PLC SCOUTS FOR INDIAN PARTNER FOR DRUG IN-LICENSING

After its in-licensing deal with Torrent Pharmaceuticals early this year for developing a hypertension drug, the $21-billion Anglo-Swedish pharma major AstraZeneca Plc is scouting for more in-licensing partners from the country. AstraZeneca has been under pressure from the Wall Street to maintain a growth rate of 12% even as two of the company's high-profile drug candidates had to be dropped last year and its new drug pipelines thinned down drastically.

Financial Express (http://www.financialexpress.com/fe_full_story.php?content_id=104428)